Related Experiment Video
Updated: Sep 29, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
Nour Abuhadra1, Shane Stecklein2, Priyanka Sharma3
1Breast Medicine Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
Triple-negative breast cancer (TNBC) accounts for approximately 15%-20% of breast cancers diagnosed worldwide, which amounts to almost 200 000 cases each year. Although historically TNBC is considered difficult to treat with a poor prognosis, there is emerging evidence showing excellent response rates in a subset of TNBC patients. Attempts to de-escalate chemotherapy in hormone-receptor-positive (HR+) and HER2-neu amplified breast cancer subtypes have been successful. At present, robust strategies to personalize therapy in early-stage TNBC do not exist, and despite excellent response rates in a subset of patients, all patients are exposed to the same several cycles of cytotoxic chemotherapy. Personalizing therapy in TNBC represents a challenge due to the scarcity of treatment options outside of cytotoxic chemotherapy and limited predictive and prognostic biomarkers to tailor treatment. Recent developments in understanding TNBC biology have sparked interest in exploring treatment optimization and personalization with the goal of achieving excellent response rates and long-term clinical outcomes, while simultaneously reducing physical, psychological, and financial toxicities for select patients. Here, we provide an update on the current evidence to support future studies examining de-escalating chemotherapy in patients with low-risk TNBC and adjuvant intensification strategies to improve outcomes for patients who are at high risk for systemic failure despite current standard-of-care treatments.
Insights
Triple-negative breast cancer (TNBC) treatment personalization is challenging. Future studies will explore de-escalating chemotherapy for low-risk patients and intensifying treatment for high-risk TNBC patients.
Area of Science:
- Oncology
- Medical Oncology
- Breast Cancer Research
Background:
- Triple-negative breast cancer (TNBC) comprises 15-20% of global breast cancer diagnoses, presenting significant treatment challenges and historically poor prognoses.
- While some TNBC patients show excellent response rates, current treatment strategies lack personalization, exposing all patients to cytotoxic chemotherapy.
- Personalizing TNBC therapy is difficult due to limited treatment options beyond chemotherapy and a scarcity of predictive biomarkers.
Purpose of the Study:
- To review current evidence for optimizing and personalizing TNBC therapy.
- To support future research on de-escalating chemotherapy in low-risk TNBC.
- To identify strategies for adjuvant treatment intensification in high-risk TNBC.
Main Methods:
- Review of current scientific literature and clinical evidence regarding TNBC treatment.
- Analysis of emerging data on TNBC biology and treatment response.
- Synthesis of findings to inform future clinical trial design.
Main Results:
- Evidence suggests a subset of TNBC patients respond exceptionally well to treatment.
- Successful chemotherapy de-escalation strategies exist for other breast cancer subtypes (HR+, HER2-neu amplified).
- The need for personalized treatment strategies and predictive biomarkers in TNBC is highlighted.
Conclusions:
- Personalizing TNBC therapy is crucial to improve outcomes and reduce treatment toxicities.
- Future research should focus on de-escalating chemotherapy for low-risk TNBC patients.
- Adjuvant treatment intensification strategies are needed for high-risk TNBC patients to prevent systemic failure.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:21Cancer Survival Analysis
02:56Treatment Resistant Cancers